The American Association for Cancer Research launched two career development awards to further diversity, equity, and inclusion in cancer research: one for basic, translational, or population sciences research, and the other for clinical cancer research.
In the field of radiation oncology there is currently tremendous excitement about the delivery of radiation at much higher dose rates than typically used clinically.
A single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival benefit versus Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.
The phase III EMERALD study found that when used as a monotherapy for the treatment of ER+/HER2- advanced or metastatic breast cancer, elacestrant significantly improved progression-free survival in the overall population and in patients with tumors harboring estrogen receptor 1 mutations, compared to the standard of care.
CoImmune, Inc. and Memorial Sloan Kettering Cancer Center entered a license and collaboration agreement to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors.
Memorial Sloan Kettering Cancer Center researchers assessed patient satisfaction and preferences for telemedicine, finding that 45% of people with cancer preferred telemedicine, while 34% preferred office visits and 21% had no preference.
The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumors express PD-L1 (CPS ≥10) and who have not received prior chemotherapy for metastatic disease.
The European Commission approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score ≥ 5.
Point32Health and Takeda Pharmaceuticals America, Inc. signed a risk-sharing agreement around Takeda’s Alunbrig (brigatinib), a potent and selective tyrosine kinase inhibitor that is approved for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
Congress needs to increase the FY22 base budgets of NIH and NCI by $3.2 billion and $1.1 billion, respectively, over FY21 levels, the American Association for Cancer Research said in its 2021 Cancer Progress Report.
